We use cookies for a better user experience. Read our Privacy Policy

I Agree

Neuropathic Pain Therapeutics Market

Neuropathic Pain Therapeutics Market (Drug Class: Anticonvulsants, Antidepressants, NSAIDs, Opioids, Steroids, and Others; Indication: Diabetic Neuropathy, Post-herpetic Neuralgia, Cancer-related Pain, Spinal Cord Injury, and Others; Route of Administration: Oral, Topical, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Research and Development Coupled with Launch of New Drugs to Boost Market

Neuropathic pain is a chronic condition wherein pathological pain continues even after the cause of the pain is eliminated. Over the past few decades, scientists and researchers have been increasingly focusing on the discovery of novel therapeutics that are essential to interrupt the signaling cascades required to manage various forms of neuropathic pain. Research and development are expected to play a major role in the overall development of the neuropathic pain therapeutics market during the forecast period. Neuropathic pain is a chronic disease that affects nearly 8% of the global population and continues to remain a major socioeconomic and medical issue.

Some of the most common pharmacological treatments to address neuropathic pain that are widely deployed include tricyclic antidepressants (amitriptyline), repurposed antiepileptic (gabapentin, pregabalin), opioids, and steroids. However, these medications bring along a range of side effects due to which, added pressure is being applied to participants operating in the neuropathic pain therapeutics market to discover new treatment types and approaches. Consistent research and development are being carried out to investigate cellular and molecular mechanisms underlying the switch from nociceptive responses to noxious stimuli to neuropathic pain.

Several players in the market are focusing on attaining approval from the FDA and expanding their product portfolio to gain an advantage in the current market landscape. At the back of these factors, along with growing collaborations between researchers and drug developers, the global neuropathic pain therapeutics market is expected to reach a market value of ~US$ 10.2 Bn by the end of 2030.

To know the scope of our report Get a Sample on Neuropathic Pain Therapeutics Market 

Market Participants Focus on Launch of New Drugs, Pipeline Therapeutics, and FDA Approval

Due to the exponential rise in the number of individuals suffering from neuropathic pain, research and development activities have accelerated at a rapid pace. Market participants are increasingly focusing on launching new medication to address neuropathic pain by investing in research and collaborating with other stakeholders in the supply chain. In addition, gaining approval from the FDA in a relatively short period of time continues to remain a major challenge for players operating in the current neuropathic pain therapeutics market.

Get a glimpse of the in-depth analysis through our Report Brochure

Market players in different regions are opting for different growth strategies to gain an edge in the current market landscape. For instance, in April 2019, Daiichi Sankyo Company announced the launch of Tarlige ® Tablets for neuropathic treatment in Japan. The company revealed that the newly launched drug is likely to benefit patients who are suffering from peripheral neuropathic pain. While small-scale development of new drugs continues to gain momentum, several market players are increasingly focusing on collaborations to expand their existing product portfolio. For instance, in March 2019, Merck & Co., announced its plans of developing a new range of neuropathic pain treatments by leveraging technologies developed by FMedSci- a joint collaboration between two players. The company further revealed that the collaboration could potentially generate ~US$ 344 Mn in revenue for King’s College London. The collaboration is also aimed at addressing the unmet clinical requirements and developing new solutions to treat neuropathic pain. Such collaborations and joint ventures in the current market landscape are likely to positively impact the overall growth of the neuropathic pain therapeutics market.

Supply-chain Challenges May Hinder Market Growth, Number of Procedural Visits to Decline

As the healthcare sector around the world is predominantly engaged in containing the spread of the novel coronavirus, as a result, a number of surgical procedures, outpatient procedures, and drug development projects has either been delayed or completely canceled. Due to the growing number of hurdles put forward by the COVID-19 pandemic, the healthcare sector is finding new ways to address the requirements of patients suffering from chronic conditions, including neuropathic pain. Companies in the neuropathic pain therapeutics market are expected to focus on exploring different strategies to ensure the continuity in drug development particularly for opioids, biopsychosocial management, anti-inflammatory drugs, etc. The growing evidence stating that chronic pain patients are at a higher risk of getting infected by COVID-19 is another factor that is expected to provide a boost to drug development and research amid the ongoing COVID-19 pandemic.

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The global neuropathic pain therapeutics market is expected to grow at a moderate CAGR of ~5% during the forecast period. The market growth can be primarily linked to a host of factors, including growth in the elderly population worldwide, research and development activities, collaborations between pharmaceutical companies and research institutes, and launch of new drugs. Neuropathic pain therapeutics market players should largely focus on expanding their product portfolio and gain approval from the FDA for their products. Addressing the bottlenecks in the supply chain amid the ongoing COVID-19 pandemic should take center stage. In addition, market participants should also focus on curating effective business continuity strategies to gain an advantage in the current market landscape.  

Neuropathic Pain Therapeutics Market: Overview

  • Neuropathic pain is treated by different medicines than pain from damaged tissue. Medicines such as paracetamol or ibuprofen are probably not effective in neuropathic pain, while medicines that are sometimes used to treat depression or epilepsy can be very effective for some people with neuropathic pain.
  • Prevalence of neuropathic pain among people of color and Hispanics was consistently higher than Caucasians in each age- and sex group. The highest prevalence of neuropathic pain was among Hispanic men 35–44 years (32.4%) and 45–54 years (24.2%) old.

Neuropathic Pain Therapeutics Market: Drivers

  • Rise in prevalence of diabetic neuropathy and other targeted diseases boosts the growth of the global neuropathic pain therapeutics market. Prevalence of peripheral neuropathy is estimated to be between 6% and 51% among adults with diabetes depending on age, duration of diabetes, glucose control, and type 1 versus type 2 diabetes. Diabetic neuropathy is the primary risk factor for the development of diabetic foot ulcers and is implicated in 50% to 75% of non-traumatic amputations.
  • Surveys conducted in the general population across Europe reported that the prevalence of neuropathic pain was 7% in 2017. Prevalence data from the International Diabetes Federation estimates that foot ulcers develop in 9.1 million to 26.1 million people with diabetes globally each year.

Increase in Adoption of Pain Management Therapeutics among End Users

  • Pain leads to severe complications if proper care or treatment is not taken. Doctors usually prescribe medicines in the initial stages of pain, followed by other treatment options. Prescription drugs are easy and cost-effective to use at individual level without any ambiguity. Increased awareness about available medications for neuropathic pain management propels the consumption and acceptance of pain management drugs over other treatment options.
  • Hence, high availability, easy access, high awareness, cost-effectiveness, and quick relief provide neuropathic pain management therapeutics a cutting edge over other treatment options

Market Segmentation: Neuropathic Pain Therapeutics Market

  • In terms of drug class, the global neuropathic pain therapeutics market has been divided into anticonvulsants, antidepressants, NSAIDs, opioids, steroids, and others. The antidepressants segment has been bifurcated into tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs).
  • Based on indication, the global neuropathic pain therapeutics market has been classified into diabetic neuropathy, post-herpetic neuralgia, cancer-related pain, spinal cord injury, and others
  • In terms of route of administration, the global neuropathic pain therapeutics market has been classified into oral, topical, and others
  • Based on distribution channel, the global neuropathic pain therapeutics market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies
  • Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030 along with market size estimations.

Regional Overview: Neuropathic Pain Therapeutics Market

  • In terms of region, the global neuropathic pain therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • Rise in adoption of neuropathic pain therapeutics for treatment and increase in number of clinical trials for the development of these products for different disorders drive the market in North America
  • The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market share and in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the market
  • Leading players analyzed in the report are 
    • Pfizer
    • Novartis AG
    • AstraZeneca
    • GlaxoSmithKline
    • Eli Lilly and Company
    • Mallinckrodt Pharmaceuticals
    • Johnson & Johnson
    • Abbott
    • Endo Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc.
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Neuropathic Pain Therapeutics Market – Segmentation

TMR’s study on the global neuropathic pain therapeutics market includes information divided into five segments: drug class, indication, route of administration, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global neuropathic pain therapeutics market have been discussed in detail.

Drug Class

Anticonvulsants

Antidepressants

NSAIDs

Opioids

Steroids

Others

Indication

Diabetic Neuropathy

Post-herpetic Neuralgia

Cancer-related Pain

Spinal Cord Injury

Others

Route of Administration

Oral

Topical

Others

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Neuropathic Pain Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of neuropathic pain therapeutics market?

Neuropathic pain therapeutics market is expected to reach US$ 10.2 Bn by the end of 2030

What is the anticipated CAGR of the neuropathic pain therapeutics market in the forecast period?

Neuropathic pain therapeutics market is expected to grow at a moderate CAGR of ~5% from 2020 to 2030

What are the key driving factors for the growth of the neuropathic pain therapeutics market?

Neuropathic pain therapeutics market is driven by rise in Geriatric Population and Prevalence of Diabetic Neuropathy

Which is the rising prominent segment in the neuropathic pain therapeutics market?

The anticonvulsants segment dominated the global neuropathic pain therapeutics market and the trend is likely to continue during the forecast period

Who are the key players in the neuropathic pain therapeutics market?

Key players in the global neuropathic pain therapeutics market include Pfizer, Novartis AG, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Mallinckrodt Pharmaceuticals

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neuropathic Pain Therapeutics Market 

4. Market Overview

    4.1.  Introduction & Overview

    4.2. Product Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities 

    4.4. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, 2018–2030

5. Market Outlook 

    5.1. Pipeline Analysis 

    5.2. Treatment Guidelines

    5.3. COVID-19 Pandemics Impact on Industry 

6. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        6.2.1. Anticonvulsants

        6.2.2. Antidepressants

            6.2.2.1. Tricyclic Antidepressants

            6.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

        6.2.3. NSAIDs

        6.2.4. Opioids

        6.2.5. Steroids

        6.2.6. Others 

    6.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class

7. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Indication, 2018–2030

        7.2.1. Diabetic Neuropathy

        7.2.2. Post-herpetic Neuralgia

        7.2.3. Cancer-related Pain

        7.2.4. Spinal Cord Injury

        7.2.5. Others

    7.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication

8. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Route of Administration, 2018–2030

        8.2.1. Oral

        8.2.2. Topical

        8.2.3. Others

    8.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration

9. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition

    9.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        9.2.1. Hospital Pharmacies

        9.2.2. Retail Pharmacies

        9.2.3. Online Pharmacies

    9.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel

10. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region

11. North America Neuropathic Pain Therapeutics Market Analysis and Forecast

    11.1. Introduction

    11.2. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        11.2.1. Anticonvulsants

        11.2.2. Antidepressants

            11.2.2.1. Tricyclic Antidepressants

            11.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

        11.2.3. NSAIDs

        11.2.4. Opioids

        11.2.5. Steroids

        11.2.6. Others

    11.3. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        11.3.1. Diabetic Neuropathy

        11.3.2. Post-herpetic Neuralgia

        11.3.3. Cancer-related Pain

        11.3.4. Spinal Cord Injury

        11.3.5. Others

    11.4. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        11.4.1. Oral

        11.4.2. Topical

        11.4.3. Others

    11.5. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Neuropathic Pain Therapeutics Market Attractiveness Analysis

        11.7.1. By Drug Class

        11.7.2. By Indication

        11.7.3. By Route of Administration

        11.7.4. By Distribution Channel

        11.7.5. By Country 

12. Europe Neuropathic Pain Therapeutics Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        12.2.1. Anticonvulsants

        12.2.2. Antidepressants

            12.2.2.1. Tricyclic Antidepressants

            12.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

        12.2.3. NSAIDs

        12.2.4. Opioids

        12.2.5. Steroids

        12.2.6. Others

    12.3. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        12.3.1. Diabetic Neuropathy

        12.3.2. Post-herpetic Neuralgia

        12.3.3. Cancer-related Pain

        12.3.4. Spinal Cord Injury

        12.3.5. Others

    12.4. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        12.4.1. Oral

        12.4.2. Topical

        12.4.3. Others

    12.5. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis

        12.7.1. By Drug Class

        12.7.2. By Indication

        12.7.3. By Route of Administration

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. Asia Pacific Neuropathic Pain Therapeutics Market Analysis and Forecast

    13.1. Introduction

    13.2. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        13.2.1. Anticonvulsants

        13.2.2. Antidepressants

            13.2.2.1. Tricyclic Antidepressants

            13.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

        13.2.3. NSAIDs

        13.2.4. Opioids

        13.2.5. Steroids

        13.2.6. Others

    13.3. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        13.3.1. Diabetic Neuropathy

        13.3.2. Post-herpetic Neuralgia

        13.3.3. Cancer-related Pain

        13.3.4. Spinal Cord Injury

        13.3.5. Others

    13.4. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        13.4.1. Oral

        13.4.2. Topical

        13.4.3. Others

    13.5. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis

        13.7.1. By Drug Class

        13.7.2. By Indication

        13.7.3. By Route of Administration

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region

14. Latin America Neuropathic Pain Therapeutics Market Analysis and Forecast

    14.1. Introduction

    14.2. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        14.2.1. Anticonvulsants

        14.2.2. Antidepressants

            14.2.2.1. Tricyclic Antidepressants

            14.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

        14.2.3. NSAIDs

        14.2.4. Opioids

        14.2.5. Steroids

        14.2.6. Others

    14.3. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        14.3.1. Diabetic Neuropathy

        14.3.2. Post-herpetic Neuralgia

        14.3.3. Cancer-related Pain

        14.3.4. Spinal Cord Injury

        14.3.5. Others

    14.4. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        14.4.1. Oral

        14.4.2. Topical

        14.4.3. Others

    14.5. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis

        14.7.1. By Drug Class

        14.7.2. By Indication

        14.7.3. By Route of Administration

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region

15. Middle East & Africa Neuropathic Pain Therapeutics Market Analysis and Forecast

    15.1. Introduction

    15.2. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        15.2.1. Anticonvulsants

        15.2.2. Antidepressants

            15.2.2.1. Tricyclic Antidepressants

            15.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

        15.2.3. NSAIDs

        15.2.4. Opioids

        15.2.5. Steroids

        15.2.6. Others

    15.3. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        15.3.1. Diabetic Neuropathy

        15.3.2. Post-herpetic Neuralgia

        15.3.3. Cancer-related Pain

        15.3.4. Spinal Cord Injury

        15.3.5. Others

    15.4. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        15.4.1. Oral

        15.4.2. Topical

        15.4.3. Others

    15.5. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

    15.6. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis

        15.7.1. By Drug Class

        15.7.2. By Indication

        15.7.3. By Route of Administration

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Competition Matrix

    16.2. Market Share Analysis, by Company, 2019

    16.3. Company Profiles

        16.3.1. Novartis AG 

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Company Financials

            16.3.1.3. Growth Strategies

            16.3.1.4. SWOT Analysis

        16.3.2. GlaxoSmithKline plc 

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Company Financials

            16.3.2.3. Growth Strategies

            16.3.2.4. SWOT Analysis

        16.3.3. AstraZeneca 

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Company Financials

            16.3.3.3. Growth Strategies

            16.3.3.4. SWOT Analysis

        16.3.4. Pfizer, Inc. 

            16.3.4.1. Company Overview (HQ, Business Segments)

            16.3.4.2. Company Financials

            16.3.4.3. Growth Strategies

            16.3.4.4. SWOT Analysis

        16.3.5. Eli Lilly and Company

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Company Financials

            16.3.5.3. Growth Strategies

            16.3.5.4. SWOT Analysis

        16.3.6. Mallinckrodt Pharmaceuticals

            16.3.6.1. Company Overview (HQ, Business Segments)

            16.3.6.2. Company Financials

            16.3.6.3. Growth Strategies

            16.3.6.4. SWOT Analysis

        16.3.7. Johnson & Johnson 

            16.3.7.1. Company Overview (HQ, Business Segments)

            16.3.7.2. Company Financials

            16.3.7.3. Growth Strategies

            16.3.7.4. SWOT Analysis

        16.3.8. Abbott 

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Company Financials

            16.3.8.3. Growth Strategies

            16.3.8.4. SWOT Analysis

        16.3.9. Endo Pharmaceuticals, Inc. 

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Company Financials

            16.3.9.3. Growth Strategies

            16.3.9.4. SWOT Analysis

        16.3.10. Teva Pharmaceutical Industries Limited

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Company Financials

            16.3.10.3. Growth Strategies

            16.3.10.4. SWOT Analysis

        16.3.11. Merck & Co., Inc.

            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.11.2. Company Financials

            16.3.11.3. Growth Strategies

            16.3.11.4. SWOT Analysis

List of Tables

Table 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 03: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 04: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 05: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 08: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 09: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 10: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 11: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 12: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 13: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 14: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 15: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 16: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 18: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 19: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 20: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 21: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 22: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 24: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 25: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 26: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 27: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 28: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 30: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 31: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 32: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 33: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 34: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 36: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

List of Figures

Figure 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2030

Figure 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, 2018–2030

Figure 03: Market Value Share, by Drug Class, 2019

Figure 04: Market Value Share, by Disease Type, 2019

Figure 05: Market Value Share, by Route of Administration, 2019

Figure 06: Market Value Share, by Distribution Channel, 2019

Figure 07: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 08: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticonvulsants, 2018–2020

Figure 09: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antidepressants, 2018–2020

Figure 10: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NSAIDs, 2018–2020

Figure 11: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Opioids, 2018–2020

Figure 12: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Steroids, 2018–2020

Figure 13: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020

Figure 14: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 15: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 16: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetic Neuropathy, 2018–2020

Figure 17: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Post-herpetic Neuralgia, 2018–2020

Figure 18: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer-related Pain, 2018–2020

Figure 19: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Spinal Cord Injury, 2018–2020

Figure 20: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020

Figure 21: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 22: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 23: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2018–2020

Figure 24: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2018–2020

Figure 25: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020

Figure 26: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 27: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 28: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018–2030

Figure 29: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018–2030 

Figure 30: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2018–2030

Figure 31: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 32: Global Neuropathic Pain Therapeutics Market, by Region, 2019 and 2030

Figure 33: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region, 2020–2030

Figure 34: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 35: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 36: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 37: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 38: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 39: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 40: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 41: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 42: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 43: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country, 2019 and 2030

Figure 44: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country, 2020–2030

Figure 45: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 46: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 47: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 48: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 49: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 50: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 51: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 52: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 53: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 54: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 55: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 56: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 57: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 58: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 59: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 60: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 61: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 62: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 63: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 64: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 65: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 66: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 67: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 68: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 69: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 70: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 71: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 72: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 73: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 74: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 75: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 76: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 77: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 78: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 79: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 80: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 81: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 82: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 83: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 84: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 85: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 86: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 87: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 88: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

735

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved